Effect of Health Education Combined with Wuqinxi on Community-Dwelling Patients with Hypertension

Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v6i3.4423

Manli Ding

PICH College of Modern Services, Shanghai Industrial and Commercial Polytechnic, Shanghai 201806, China

Abstract

Objective: To explore the clinical efficacy of health education combined with Wuqinxi exercise in managing essential hypertension. Methods: Eighty patients were randomly assigned to either an experimental group (health education + Wuqinxi) or a control group (health education alone). The effects of the 10-week intervention were evaluated using the following indicators: blood pressure (SBP/DBP), blood lipids (TG/TC). Results: The experimental group showed significantly greater improvements compared to the control group (*p*<0.05): TC decreased by 1.73 mmol/L, TG decreased by 0.83 mmol/L; SBP decreased by 17.95 mmHg, DBP decreased by 13.53 mmHg. Conclusion: Wuqinxi combined with health education effectively controls blood pressure and blood lipids.

Keywords

essential hypertension; Wuqinxi; health management

Full Text

PDF - Viewed/Downloaded: 2 Times

References

[1] Zhao X, Chen Y, Yang G, et al. Initial treatment with a single capsule containing half-dose quadruple therapy vs standard-dose dual therapy in hypertensive patients (QUADUAL): Study protocol for a randomized, blinded, crossover trial. Am Heart J. 2023;264:10-19.
[2] Ritchey MD, Cathleen G, Gregory W, et al. Potential need for expanded pharmacologic treatment and lifestyle modification services under the 2017 ACC/AHA Hypertension Guideline. J Clin Hypertens. 2018;20(1):1377-1391.
[3] Collaborators GRF. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2021;396:1223-1249.
[4] He YF, Gong Z, Jia RY, et al. Visual analysis and trend exploration of the antihypertensive drug telmisartan based on bibliometrics. Chin J Appl Chem. 2024;41(04):593-598.
[5] Frishman WH. Beta-adrenergic receptor blockers. Adverse effects and drug interactions. Hypertension. 2020;11(3 Pt 2):II21-9.

Citing this article:

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License